Welcome to our dedicated page for Precipio SEC filings (Ticker: PRPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precipio, Inc. filings document the public-company disclosures of a specialty cancer diagnostics issuer with Pathology Services and Products operations. Its Form 8-K reports include Regulation FD updates for shareholder calls and investor presentations, furnished financial results, and material-event disclosures related to corporate communications and operating performance.
The company’s proxy materials describe annual meeting procedures, stockholder voting matters, governance, and access to annual reporting materials. Other filings document capital-structure matters, including common stock activity and the termination of an at-the-market sales agreement, alongside formal exhibits and disclosures tied to Precipio’s diagnostics business and shareholder communications.
Valauri Christina Rizopoulos reported acquisition or exercise transactions in this Form 4 filing.
Precipio, Inc. director Christina Rizopoulos received an equity compensation award of 108 shares of common stock on July 15, 2026. The shares were granted at a value of $25.24 per share as consideration in lieu of cash payment for her Board service for Q2-26.
Following this award, she holds 5,628 Precipio common shares directly.
Cossman Jeffrey reported acquisition or exercise transactions in this Form 4 filing.
Precipio, Inc. director Jeffrey Cossman received a grant of 416 shares of common stock on July 15, 2026, as equity compensation in lieu of cash fees for Q2-26 Board of Directors service.
After this award, he holds 16,549 common shares directly.
Cohen David Seth reported acquisition or exercise transactions in this Form 4 filing.
Precipio, Inc. director David Seth Cohen received a grant of 520 shares of common stock on July 15, 2026, as compensation for Q2-26 board service, taken in stock in lieu of cash. The award, valued at $25.24 per share, increased his directly held position to 55,199 shares.
Precipio, Inc. reported the results of its Annual Meeting of stockholders. Holders of 1,063,293 common shares, or 59.57% of the 1,784,830 shares entitled to vote, were present in person or by proxy, so a quorum was reached.
Stockholders elected Richard Sandberg, Christina Valauri, and Jeffrey Cossman, M.D. as Class II directors with terms expiring in 2029. They also ratified the appointment of CBIZ CPAs, P.C. as the company’s independent registered public accounting firm for the year ending December 31, 2026. No other matters were brought to a vote.
Precipio, Inc. director Richard A. Sandberg reported an indirect open-market sale related to shares of the company’s common stock. On May 21, 2026, Wythburn Associates, Ltd., an entity 94% owned jointly by Sandberg and his spouse, sold 900 shares at an average price of $25.0193 per share.
After this sale, Wythburn Associates held 3,000 shares of Precipio common stock. Separate entries show Sandberg with 25,000 shares held indirectly through a Roth IRA and 8,142 shares held directly in his own name. The filing states that Sandberg disclaims beneficial ownership of Wythburn’s securities except to the extent of his pecuniary interest.
Precipio, Inc. director Richard A. Sandberg reported net open-market sales of 3,134 shares of common stock. On May 19–20, 2026, he sold 2,034 shares held directly at prices around $24.89 per share, leaving 8,142 directly owned shares.
Additional sales of 600 and 500 shares were made by Wythburn Associates, Ltd, an entity 94% owned jointly by Sandberg and his spouse, at weighted average prices near $24.42 and $25.00. Sandberg disclaims beneficial ownership of these Wythburn shares except for his pecuniary interest. After these transactions, Wythburn held 3,900 shares, and a Roth IRA for Sandberg’s benefit held 25,000 shares.
PRPO submitted Form 144 reporting proposed or completed sales of Common Stock by holders. The filing lists open-market dispositions of 500 shares (05/22/2025), 101 shares (05/27/2025), and 1,399 shares (05/30/2025) with corresponding sale dates in late May–June 2025. It also shows 2,034 shares issued as equity compensation on 04/15/2024.
Precipio, Inc. reported sharply higher activity but continued losses for the three months ended March 31, 2026. Net sales rose to $6.7M from $4.9M, driven by service revenue, as cases processed increased to 4,912 from 3,021. Gross profit improved to $2.7M, though gross margin dipped to 41% from 43% due to lower average price per case.
The company recorded a net loss of $1.4M versus $0.9M a year earlier, with higher operating expenses including $1.0M of stock-based compensation. Cash was $2.6M and working capital $2.1M, with slightly positive operating cash flow of $0.1M. Management states there is substantial doubt about Precipio’s ability to continue as a going concern without additional revenue growth or financing.
Precipio, Inc. is organizing a Q1-2026 shareholder update call on May 18, 2026 at 5:00 PM ET. Management plans to discuss the company’s current core businesses and overall performance, strategy, and growth initiatives.
For the first time, the quarterly update will feature a dedicated, moderated live Q&A session, allowing investors and other listeners to submit questions during the call or in advance by email. Participants can join by calling 646.307.1865, and a replay will be available on the Investors section of Precipio’s website.